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SARS-CoV-2 has infected 47 million individuals and is responsible for over 1.2 million deaths 31 
to date. Infection is associated with development of variable levels of antibodies with 32 
neutralizing activity that can protect against infection in animal models. Antibody levels 33 
decrease with time, but the nature and quality of the memory B cells that would be called 34 
upon to produce antibodies upon re-infection has not been examined. Here we report on the 35 
humoral memory response in a cohort of 87 individuals assessed at 1.3 and 6.2 months after 36 
infection. We find that IgM, and IgG anti-SARS-CoV-2 spike protein receptor binding 37 
domain (RBD) antibody titers decrease significantly with IgA being less affected. 38 
Concurrently, neutralizing activity in plasma decreases by five-fold in pseudotype virus 39 
assays. In contrast, the number of RBD-specific memory B cells is unchanged. Memory B 40 
cells display clonal turnover after 6.2 months, and the antibodies they express have greater 41 
somatic hypermutation, increased potency and resistance to RBD mutations, indicative of 42 
continued evolution of the humoral response. Analysis of intestinal biopsies obtained from 43 
asymptomatic individuals 3 months after COVID-19 onset, using immunofluorescence, 44 
electron tomography or polymerase chain reaction, revealed persistence of SARS-CoV-2 in 45 
the small bowel of 7 out of 14 volunteers. We conclude that the memory B cell response to 46 
SARS-CoV-2 evolves between 1.3 and 6.2 months after infection in a manner that is 47 
consistent with antigen persistence.  48 
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Antibody responses to SARS-CoV-2 were initially characterized in a cohort of COVID-19-50 
convalescent individuals approximately 40 days (1.3 months) after infection 1. Between 31 August 51 
and 16 October 2020, 100 participants returned for a 6-month follow-up study visit. Although 52 
initial criteria allowed enrollment of close contacts of individuals diagnosed with RT-PCR 53 
confirmed SARS-CoV-2 infection 1, 13 of the contacts did not seroconvert and were excluded 54 
from further analyses. The remaining 87 participants with RT-PCR–confirmed COVID-19 55 
diagnosis and/or seroconversion returned for analysis approximately 191 days (6.2 months, range: 56 
165-223 days) after the onset of symptoms. In this cohort, symptoms lasted for a median of 12 57 
days (0–44 days) during the acute phase, and 10 (11%) of the participants were hospitalized. 58 
Consistent with other reports 2,3, 38 (44%) of the participants reported persistent long-term 59 
symptoms attributable to COVID-19 (Methods and Supplementary Tables 1 and 2). The duration 60 
and severity of symptoms during acute disease was significantly greater among participants with 61 
persistent post-acute symptoms at the second study visit (Extended Data Fig. 1m-o). Importantly, 62 
all 87 participants tested negative for SARS-CoV-2 at the 6-month follow-up study visit using an 63 
approved saliva-based PCR assay (Methods). Participant demographics and clinical characteristics 64 
are shown in Supplementary Tables 1,2. 65 
 66 
Antibody reactivity in plasma to RBD and nucleoprotein (N) was measured by validated 67 
serological assays 1,4,5. Two anti-RBD assays were strongly correlated (anti-RBD IgG and IgM 68 
ELISA/Pylon-IgG and IgM at 1.3 months, r=0.9200 and r=0.7543, p < 0.0001, respectively. 69 
Extended Data Fig 2). The IgM, IgG and IgA anti-RBD antibodies in plasma decreased 70 
significantly between 1.3 and 6.2 months (Fig. 1a-c). However, the drop in RBD-binding activity 71 
differed significantly by isotype, IgM showed the greatest decrease in anti-RBD reactivity (53%), 72 
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followed by IgG (33%) while IgA decreased by only 15% (Fig. 1e). In all cases the magnitude of 73 
the decrease was inversely proportional to and directly correlated with the initial antibody levels 74 
such that individuals with higher initial levels showed greater relative changes (Fig. 1f-i). In 75 
contrast, the Roche anti-N assay5 showed a small but significant increase (19%) in reactivity 76 
between the two time points that did not correlate with IgA anti-RBD ELISAs and was modestly 77 
correlated with IgM at 1.3 months and IgG anti-RBD reactivity at both time points, respectively 78 
(Fig. 1d and Extended Data Fig. 2i-n). Notably, individuals with persistent post-acute symptoms 79 
had significantly higher anti-RBD IgG and anti-N antibody levels at both study visits (Extended 80 
Data Fig. 1a-j). 81 
 82 
Plasma neutralizing activity was measured using an HIV-1 virus pseudotyped with the SARS-83 
CoV-2 spike protein1,6. Consistent with other reports the geometric mean half-maximal 84 
neutralizing titer (NT50) in this group of 87 participants was 401 and 78 at 1.3 and 6.2 months, 85 
respectively, representing a five-fold decrease (Fig. 1j-k)7,8. Neutralizing activity was directly 86 
correlated with the IgG anti-RBD ELISA measurements (Extended data Fig. 2o-p). Moreover, the 87 
absolute magnitude of the decrease in neutralizing activity was inversely proportional to and 88 
directly correlated with the neutralizing activity at the earlier time point (Fig. 1l). We conclude 89 
that antibodies to RBD and plasma neutralizing activity decrease significantly but remain 90 
detectable 6 months after infection with SARS-CoV-2 in the majority of individuals. 91 
   92 
Whereas plasma cells are the source of circulating antibodies, memory B cells contribute to recall 93 
responses. To identify and enumerate the circulating SARS-CoV-2 memory B cell compartment 94 
we used flow cytometry to isolate individual B lymphocytes with receptors that bound to RBD 1 95 
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(Fig. 2a and b, and Extended data Fig. 3). Notably, the percentage of RBD-binding memory B 96 
cells increased marginally between 1.3 and 6.2 months in 21 randomly selected individuals (Fig. 97 
2b).  98 
 99 
To determine whether there were changes in the antibodies produced by memory B cells after 6.2 100 
months, we obtained 532 paired antibody heavy and light chains from the same 6 individuals that 101 
were examined at the earlier time point 1 (Supplementary Table 3). There was no significant 102 
difference in IGV gene representation at the two time points, including the over-representation of 103 
the IGHV3-30 and 3-53 gene segments 1,9-14 (Extended data Fig. 4). In keeping with this 104 
observation, and similar to the earlier time point, antibodies that shared the same IGHV and IGLV 105 
genes comprised 8.6% of all sequences in different individuals (Extended data Fig. 5a). As might 106 
be expected, there was a small but significant overall increase in the percentage of IgG-expressing 107 
anti-RBD memory cells, from 47% to 57% (p=0.011, Extended data Fig. 5b-d). Consistent with 108 
the fractional increase in IgG memory cells, the extent of somatic hypermutation for both IGH and 109 
IGL differed significantly in all 6 individuals between the two time points. Whereas the average 110 
number of nucleotide mutations in IGH and IGL was only 4.2 and 2.8 at the first time point, these 111 
values were increased to 11.7 and 6.5 at the second time point (p<0.0001, Fig. 2c and Extended 112 
data Fig. 6). In contrast, the overall average IGH and IGL CDR3 length and hydrophobicity were 113 
unchanged (Extended data Fig. 7).   114 
 115 
Similar to the earlier time point, we found expanded clones of memory B cells at 6.2 months 116 
including 23 that appeared at both time points. However, expanded clones accounted for only 117 
12.4% of all antibody sequences after 6.2 months compared to 32% after 1.3 months (p = 0.0225, 118 
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Fig. 2d-e). In addition, the overall clonal composition of the memory compartment differed at the 119 
two time points in all individuals examined (Fig. 2d). Forty-three expanded clones that were 120 
present at the earlier time point were not detectable after 6.2 months while 22 new expanded clones 121 
appeared. In addition, the relative distribution of clones that appeared at both time points also 122 
varied. For example, the dominant clones in COV21 and COV57 representing 9.0% and 16.7% of 123 
all sequences, respectively, were reduced to 1.1% and 1.9% of all sequences after 6.2 months (Fig. 124 
2d and Supplementary Table 3).  We conclude that while the magnitude of the RBD-specific 125 
memory B cell compartment is conserved between 1.3 and 6.2 months after SARS-CoV-2 126 
infection, there is significant clonal turnover and antibody sequence evolution, consistent with 127 
prolonged germinal center reactions.  128 
 129 
One hundred and twenty-two representative antibodies from the 6.2-month time point were tested 130 
for reactivity to RBD (Supplementary Table 4). The antibodies that were evaluated included: (1) 131 
49 that were randomly selected from those that appeared only once; (2) 23 that appeared as singles 132 
at both 1.3 and 6.2 months; (3) 23 representatives of newly appearing expanded clones; (4) 27 133 
representatives of expanded clones appearing at both time points. One hundred and fifteen of 122 134 
of the antibodies bound to RBD indicating that flow cytometry efficiently identified B cells 135 
producing anti-RBD antibodies (Fig. 3a and Supplementary Tables 4 and 5). Taking all antibodies 136 
together, the mean ELISA EC50 was not significantly different at the two time points (Fig. 3a, 137 
Supplementary Table 4 and 1). However, comparison of the antibodies that were present at both 138 
time points revealed a significant improvement of the EC50 after 6.2 months (p= 0.0227, Fig. 3b 139 
and Extended data Fig.8a).    140 
 141 
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To determine whether the antibodies expressed by memory B cells at the late time point also 142 
showed altered breadth, we compared them to earlier clonal relatives in binding assays using 143 
control and mutant RBDs: The mutations E484K and Q493R15 were selected for resistance to class 144 
2 antibodies such as C144 and C121 that bind directly to the ACE2 interaction ridge in the RBD 145 
1,16-18 while R346S, N439K, and N440K were selected for resistance to class 3 antibodies such as 146 
C135 that do not directly interfere with ACE2 binding 1,15-18 (Fig.3c). In addition, V367F, A475V, 147 
S477N, and V483A represent circulating variants that confer complete or partial resistance to class 148 
1 and 2 antibodies 15,16,19 (Fig. 3c). Out of 52 antibody clonal pairs appearing at both time points, 149 
43 (83%) showed overall increased binding to mutant RBDs at the 6.2-month time point (Extended 150 
data Fig. 8b-k, Supplementary Table 5). For example, C144, an antibody recovered at the 1.3-151 
month time point, was unable to bind to Q493R or E484K RBDs, but all 4 of its 6.2-month clonal 152 
derivatives bound to Q493R, and one also showed binding to E484K (Fig. 3d). Overall, the most 153 
pronounced increase in binding occurred for RBD mutations in amino acid positions such as E484, 154 
Q493, N439, N440 and R346 that are critical for binding of class 2 and 3 antibodies 15,16 (Fig. 3e, 155 
Extended data Fig. 8b-k and Supplementary Table 5). 156 
 157 
Next, all 122 antibodies from the 6.2 month time point were tested for activity in a pseudotyped 158 
SARS-CoV-2 neutralization assay 1,6 (Fig. 4a, Supplementary Table 6). Consistent with RBD 159 
binding assays, the mean neutralization IC50 values were not significantly different at the two time 160 
points when all antibodies were compared (Fig. 4a and 1). However, comparison of the antibodies 161 
that were present at both time points revealed a significant improvement of the IC50 values at 6.2 162 
months (p=0.0003, Fig. 4b and Extended data Fig. 9a).       163 
 164 
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To determine whether the antibodies exhibiting altered RBD binding also show increased 165 
neutralizing breadth, we tested 5 representative antibody pairs recovered at the two time points 166 
against HIV-1 viruses pseudotyped with E484G, Q493R, and R346S mutant spike proteins (Fig. 167 
4c, Supplementary Table 6). Notably, the Q493R and E484G pseudotyped viruses were resistant 168 
to neutralization by C144; in contrast, its 6.2-month clonal derivative C051 neutralized both 169 
variants with IC50 values of 4.7 and 3.1 ng/ml respectively (Fig. 4c-d). Similarly, R346S 170 
pseudotyped viruses were resistant to C032, but a 6.2-month clonal derivative C080 neutralized 171 
this variant with an IC50 of 5.3 ng/ml (Fig. 4c, Extended data Fig. 9b-f). Consistent with the 172 
observed changes in binding and neutralizing activity several late-appearing antibodies (e.g. C051) 173 
had acquired mutations directly in or adjacent to the RBD-binding paratope (Fig. 4e, Extended 174 
data Fig. 10). We conclude that memory B cells that evolved during the observation period express 175 
antibodies with increased neutralizing potency and breadth. 176 
 177 
Antibody evolution occurs by somatic mutation and selection in germinal centers wherein antigen 178 
can be retained in the form of immune complexes on the surface of follicular dendritic cells for 179 
prolonged periods of time. Residual virus in tissues represents another potential source of antigen. 180 
SARS-CoV-2 replicates in ACE2-expressing cells in the lungs, nasopharynx and small intestine 181 
20-23, and viral RNA has been detected in stool samples even after the virus is cleared from the 182 
nasopharynx 24-26. To determine whether there might be antigen persistence in the intestine after 183 
resolution of clinical illness, we obtained biopsies from the upper and lower gastrointestinal (GI) 184 
tract of 14 individuals, an average of 4 months (range 2.8-5.5 months) after initial SARS-CoV-2 185 
diagnosis (Supplementary Table 7). Clinically approved nasopharyngeal swab PCR assays were 186 
negative in all 14 individuals at the time of biopsy. However, biopsy samples from 3 of the 14 187 
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participants produced PCR amplicons that were sequence verified as SARS-CoV-2 (Methods and 188 
Supplementary Table 7). Immunostaining was performed to determine whether viral protein was 189 
also detectable in upper and lower GI tract, with de-identified biopsies from individuals pre-dating 190 
the pandemic (n=10) serving as controls. ACE2 and SARS-CoV-2 N protein was detected in 191 
intestinal enterocytes in 5 of 14 individuals but not in historic control samples (Fig. 5a-d, Extended 192 
data Fig. 11,12 and 13, and Supplementary Table 7). When detected, immunostaining was 193 
sporadic, patchy, exclusive to the intestinal epithelium and not associated with inflammatory 194 
infiltrates (Extended data Fig. 11,12).  195 
 196 
Detection of SARS-CoV-2 RNA and N protein could represent defective viral particles and/or 197 
infected cell debris. To determine whether viral particles were present we used electron 198 
tomography to examine a tissue sample from one of the individuals who was positive by 199 
immunofluorescence (Fig. 5e-j). Particles with typical SARS-CoV-2 morphologies were found 200 
within intracellular membrane-enclosed vesicles consistent with coronavirus exit compartments in 201 
terminal ileum apical epithelial cells (Fig. 5e-h), suggesting the presence of intact virions. Particles 202 
were also found in vesicles in apical epithelial cells of the duodenum, although there were fewer 203 
and less densely-populated vesicles observed (Fig. 5i-j).  204 
 205 
Neutralizing antibodies to SARS-CoV-2 develop in most individuals after infection but decay with 206 
time 7,8,27-31. These antibodies are effective in prevention and therapy in animal models and are 207 
likely to play a role in protection from re-infection in humans 32. Although there is a significant 208 
drop in plasma neutralizing activity between 1.3 and 6.2 months, antibody titers remain measurable 209 
in most individuals 7,8,27-30,33.  210 
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 211 
Neutralizing monoclonal antibodies obtained from individuals during the early convalescence 212 
period showed remarkably low levels of somatic mutations that some investigators attributed to 213 
defects in germinal center formation 9,10,12,34-37,. Our data indicate that the anti-SARS-CoV-2 214 
memory B cell response evolves during the first 6 months after infection, with accumulation of Ig 215 
somatic mutations, and production of antibodies with increased neutralizing breadth and potency. 216 
Persistent antibody evolution occurs in germinal centers and requires that B cells are exposed to 217 
antigen trapped in the form of immune complexes on follicular dendritic cells 38. This form of 218 
antigen can be long-lived because follicular dendritic cells do not internalize immune complexes. 219 
In addition, even small amounts of persistent viral replication could contribute antigen to fuel 220 
antibody evolution. The observation that SARS-CoV-2 remains detectable in the small intestinal 221 
epithelium even 3 months after infection is consistent with the relative persistence of anti-RBD 222 
IgA antibodies and continued antibody evolution.  However, the prevalence, clinical significance, 223 
and potential infectivity of residual SARS-CoV-2 in intestinal enterocytes remain to be 224 
determined. 225 
 226 
Memory responses are responsible for protection from re-infection and are essential for effective 227 
vaccination. The observation that memory B cell responses do not decay after 6.2 months, but 228 
instead continue to evolve, is strongly suggestive that individuals who are infected with SARS-229 
CoV-2 could mount a rapid and effective response to the virus upon re-exposure.  230 
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Figures  232 
 233 
 234 
Fig. 1: Plasma antibody dynamics against SARS-CoV-2.  235 
a–d, Results of serological assays measuring plasma reactivity to RBD (a,b,c) and N protein (d) 236 
at the initial 1.3 and 6.2 month follow-up visit, respectively. a, Anti-RBD IgM. b, Anti-RBD IgG. 237 
c, Anti-RBD IgA d, Anti-N total antibodies. The normalized area under the curve (AUC) values 238 
for 87 individuals and Cut-off Index (COI) values for 80 individuals are shown in a,b,c and d for 239 
both time points, respectively. Positive and negative controls were included for validation 1. e, 240 
Relative change in plasma antibody levels between 1.3 and 6.2 months for anti-RBD IgM, IgG, 241 
IgA and anti-N total Ig, respectively. f-i, Relative change in antibody levels between 1.3 and 6.2 242 
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months plotted against the corresponding antibody levels at 1.3 months. f, Anti-RBD IgM. r = -243 
0.83, p <0.0001. g, Anti-RBD IgG. r = -0.76, p <0.0001. h, Anti-RBD IgA. r = -0.67, p <0.0001. 244 
i, Anti-N total antibodies. r = -0.23, p = 0.039. j. Ranked average half-maximal inhibitory plasma 245 
neutralizing titer (NT50) at 1.3 months (blue) and 6.2 months (red) for the 87 individuals studied. 246 
k. Graph shows NT50 for plasma collected at 1.3 and 6.2 months p <0.0001. l. Relative change in 247 
plasma neutralizing titers between 1.3 and 6.2 months plotted against the corresponding titers at 248 
1.3 months. For a-e, k plotted values and horizontal bars indicate geometric mean. Statistical 249 
significance was determined using Wilcoxon matched-pairs signed rank test in a-d, k and 250 
Friedman with Dunn’s multiple comparison test in e. The r and p values in f – I and l were 251 
determined by two-tailed Spearman’s correlations. 252 
 253 
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 254 
Fig. 2: Anti-SARS-CoV-2 RBD antibody sequences. 255 
a, Representative flow cytometry plots showing dual AlexaFluor-647–RBD- and PE–RBD-256 
binding B cells for six study individuals (gating strategy is in Extended Data Fig.3). Percentage of 257 
antigen-specific B cells is indicated. b. As in a. graph summarizes %RBD binding memory B cells 258 
in samples obtained at 1.3 and 6.2 months from 21 randomly selected individuals. Red horizontal 259 
bars indicate geometric mean values. Statistical significance was determined using Wilcoxon 260 
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matched-pairs signed rank test. c, Number of somatic nucleotide mutations in the IGVH (top) and 261 
IGVL (bottom) in antibodies obtained after 1.3 or 6.2 months from the indicated individual or all 262 
donors (right). d, Pie charts show the distribution of antibody sequences from 6 individuals after 263 
1.3 1 (upper panel) or 6.2 months (lower panel). The number in the inner circle indicates the number 264 
of sequences analyzed for the individual denoted above the circle. Pie slice size is proportional to 265 
the number of clonally related sequences. The black outline indicates the frequency of clonally 266 
expanded sequences detected in each patient. Colored slices indicate persisting clones (same IGHV 267 
and IGLV genes and highly similar CDR3s) found at both timepoints in the same patient. Grey 268 
slices indicate clones unique to the timepoint. White slices indicate singlets found at both 269 
timepoints, while the remaining white area indicates sequences isolated once. e. Graph shows 270 
relative clonality at both time points timepoints.  Red horizontal bars indicate mean values. 271 
Statistical significance was determined using two-tailed Mann–Whitney U-tests or paired t-test.  272 
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 273 
Fig. 3: Anti-SARS-CoV-2 RBD monoclonal antibody reactivity. 274 
a, Graphs show anti-SARS-CoV-2 RBD antibody reactivity. ELISA EC50 values for all antibodies 275 
measured at 1.3 1 and 122 selected monoclonal antibodies at 6.2 months. Horizontal bars indicate 276 
geometric mean. Statistical significance was determined using Mann–Whitney U-test. b, EC50 277 
values for all antibodies that appear at 1.3 and 6.2 months. Average of two or more experiments. 278 
Horizontal bars indicate geometric mean. Statistical significance was determined using Wilcoxon 279 
matched-pairs signed rank test. c, Surface representation of the RBD with the ACE2 binding 280 
footprint indicated as a dotted line and selected residues found in circulating strains (grey) and 281 
residues that mediate resistance to class 2 (red, C144) and 3 (green, C135) antibodies highlighted 282 
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as sticks. d. Graphs show ELISA binding curves for C144 (black dashed line) and its clonal 283 
relatives obtained after 6.2 months (C050-54, solid lines) binding to wild type, Q493R, R346S, 284 
and E484K mutant RBDs. e. Heat map shows log2 relative fold change in EC50 against indicated 285 
RBD mutants for 26 antibody clonal pairs obtained at 1.3 and 6.2 month with the most pronounced 286 
changes in reactivity. The participant origin for each antibody pair is indicated above. All 287 
experiments were performed at least twice. 288 
 289 
Fig.4: Anti-SARS-CoV-2 RBD monoclonal antibody neutralizing activity. 290 
a, SARS-CoV-2 pseudovirus neutralization assay. IC50 values for all antibodies measured at 1.3 291 
months1 and 122 selected antibodies at 6.2 months. Antibodies with IC50 values above 1 µg/ml 292 
were plotted at 1 µg/ml. Mean of 2 independent experiments. Red bar indicates geometric mean. 293 
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Statistical significance was determined using Mann-Whitney U-test. b, IC50 values for antibodies 294 
appearing at 1.3 and 6.2 months. Red bar indicates geometric mean. Statistical significance was 295 
determined using Wilcoxon matched-pairs signed rank test. c, IC50 values for 5 different pairs of 296 
mAb clonal relatives obtained after 1.3 (blue) or 6.2 months (red) for neutralization of wild type 297 
and mutant SARS-CoV-2 pseudovirus. Antibody IDs of the 1.3 months/6.2 months mAb pairs as 298 
indicated. d, Graph shows the normalized relative luminescence values for cell lysates of 293TACE2 299 
cells 48 hpi with SARS-CoV-2 pseudovirus harboring wt RBD or mutant RBDs (wt, Q493R, 300 
E484G, R346S RBD mutants are shown in black, red, green and blue, respectively) in the presence 301 
of increasing concentrations of mAbs C144 (1.3 months, dashed lines) or C051 (6.2 months, solid 302 
lines). e, Surface representation of two adjacent “down” RBDs (RBDA and RBDB) on a spike 303 
trimer with the C144 epitope on the RBDs highlighted in cyan and positions of amino acid 304 
mutations that accumulated in C051 compared to the parent antibody C144 highlighted as stick 305 
side chains on a Ca atom representation C051 VHVL binding to adjacent RBDs. The C051 306 
interaction with two RBDs was modeled based on a cryo-EM structure of C144 Fab bound to spike 307 
trimer 16. 308 
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Fig. 5: Immunofluorescence and electron microscopy imaging of intestinal biopsies. 310 
a, Immunofluorescence images of human enterocytes stained for EPCAM (red), DAPI (blue) and 311 
either ACE2 (green, a and c) or SARS-CoV-2 N (green, b and d) in intestinal biopsies taken 92 312 
days after COVID-19 symptom onset of participant CGI-088 in the terminal ileum (a-b) or 313 
duodenum (c-d). Arrows indicate enterocytes with detectable SARS-CoV-2 antigen. White scale 314 
bar corresponds to 100 μm. e-h, SARS-CoV-2 virions within terminal ileum of CGI-088 315 
(identified as described in methods).  e, Montaged 2D overview of a region of apical epithelium. 316 
f, Tomographic slice (1.5 nm) of a 3D reconstruction of the area of epithelial cell cytoplasm 317 
indicated by the white square in e. Two coronavirus-filled exit compartments (center) are 318 
surrounded by other membranous compartments with dissimilar contents. g, Tomographic detail 319 
of the two exit compartments, indicated by the white rectangle in f. Each compartment contains 320 
~20 presumptive SARS-CoV-2 virions. h, Detail of a single virion (indicated by white arrow in g) 321 
showing densities for the membrane bilayer (black arrowhead), punctate core structures (*), and 322 
surface spikes (red dots). i-j, SARS-CoV-2 within duodenum of CGI-088 (identified as described 323 
in methods). i, Montaged 2D overview of a region of the duodenal apical epithelium. j, 324 
Tomographic slice (1.5 nm) of a 3D reconstruction of the area of epithelial cell cytoplasm indicated 325 
by the white square in i. SARS-CoV-2 virions are localized to two smooth-walled exit 326 
compartments (white arrows). Inset in j: Detail of three presumptive SARS-CoV-2 virions from 327 
the compartment in the upper left of j. Surface spikes are indicated by red dots. M, Mitochondrion. 328 
  329 
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Methods 330 
 331 
Data reporting  332 
No statistical methods were used to predetermine sample size. The experiments were not 333 
randomized and the investigators were not blinded to allocation during experiments and outcome 334 
assessment.  335 
 336 
Study participants. Previously enrolled study participants 1 were asked to return for a 6-month 337 
follow-up visit at the Rockefeller University Hospital in New York from August 31 through 338 
October 16, 2020. Eligible participants were adults aged 18-76 years and were either diagnosed 339 
with SARS-CoV-2 infection by RT-PCR (cases), or were close contacts (e.g., household, co-340 
workers, members of same religious community) with someone who had been diagnosed with  341 
SARS-CoV-2 infection by RT-PCR (contacts). Close contacts without seroconversion against 342 
SARS-CoV-2 as assessed by serological assays (described below) were not included in the 343 
subsequent analysis. Most study participants were residents of the Greater New York City tri-state 344 
region and were asked to return approximately 6 months after the time of onset of COVID-19 345 
symptoms. Participants presented to the Rockefeller University Hospital for blood sample 346 
collection and were asked to recall the symptoms and severity of clinical presentation during the 347 
acute (first 6 weeks) and the convalescent (7 weeks until second study visit) phase of COVID-19, 348 
respectively. The severity of acute infection was assessed by the WHO Ordinal Clinical 349 
Progression/Improvement Scale (https://www.who.int/publications/i/item/covid-19-therapeutic-350 
trial-synopsis). Shortness of breath was assessed through the modified Medical Research Council 351 
(mMRC) dyspnea scale 39. Participants who presented with persistent symptoms attributable to 352 
COVID-19 were identified on the basis of chronic shortness of breath or fatigue, deficit in athletic 353 
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ability and/or three or more additional long-term symptoms such as persistent unexplained fevers, 354 
chest pain, new-onset cardiac sequalae, arthralgias, impairment of concentration/mental acuity, 355 
impairment of sense of smell/taste, neuropathy or cutaneous findings 2,3. All participants at 356 
Rockefeller University provided written informed consent before participation in the study and the 357 
study was conducted in accordance with Good Clinical Practice. 358 
 359 
Gastrointestinal biopsy cohort.  To determine if SARS-CoV-2 can persist in the gastrointestinal 360 
tract, we recruited a cohort of 14 individuals with prior diagnosis of and recovery from COVID-361 
19 illness. Eligible participants included adults, 18-76 years of age who were previously diagnosed 362 
with SARS-CoV-2 by RT PCR and presented to the gastroenterology clinics of Mount Sinai 363 
Hospital. Endoscopic procedures were performed for clinically indicated conditions as detailed in 364 
Supplementary Table 7. All participants were asymptomatic at the time of the endoscopic 365 
procedures and negative for SARS-CoV-2 by nasal swab PCR (Cycle threshold (Ct) cut-off <3840). 366 
Informed consent was obtained from all participants. The biopsy-related studies were approved by 367 
the Mount Sinai Ethics Committee/IRB (IRB 16-0583, The impact of viral infections and their 368 
treatment on gastrointestinal immune cells).  369 
 370 
SARS-CoV-2 saliva PCR test   371 
Saliva was collected into guanidine thiocyanate buffer as described 41.  RNA was extracted using 372 
either a column-based (Qiagen QIAmp DSP Viral RNA Mini Kit, Cat#61904) or a magnetic bead-373 
based method as described 42. Reverse transcribed cDNA was amplified using primers and probes 374 
validated by the CDC or by Columbia University Personalized Medicine Genomics Laboratory, 375 
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respectively, and approved by the FDA under the Emergency Use Authorization. Viral RNA was 376 
considered detected if the cycle threshold (Ct) for two viral primers/probes were <40.  377 
 378 
Blood samples processing and storage. Peripheral Blood Mononuclear Cells (PBMCs) were 379 
obtained by gradient centrifugation and stored in liquid nitrogen in the presence of FCS and 380 
DMSO. Heparinized plasma and serum samples were aliquoted and stored at -20°C or less. Prior 381 
to experiments, aliquots of plasma samples were heat-inactivated (56°C for 1 hour) and then stored 382 
at 4°C. 383 
 384 
High throughput automated serology assays 385 
Plasma samples from 80 out of 87 participants were tested by high throughput automated serology 386 
assays. The Roche Elecsys anti-SARS-CoV-2 assay was performed on Roche Cobas e411 (Roche 387 
Diagnostics, Indianapolis, IN). The Elecsys anti‐SARS‐CoV-2 assay uses a recombinant protein 388 
representing the N antigen for the determination of antibodies against SARS‐CoV‐2. This assay 389 
received Emergency Use Authorization (EUA) approval from the United States Food and Drug 390 
Administration (FDA) 5. The Pylon COVID-19 IgG and IgM assays were used to measure plasma 391 
IgG and IgM antibodies against SARS-CoV-2, respectively. Plasma samples were assayed on the 392 
Pylon 3D analyzer (ET HealthCare, Palo Alto, CA) as previously described 4.  This assay was 393 
implemented clinically as a laboratory-developed test under New York State Department of Health 394 
regulations.  Briefly, the assay was performed using a unitized test strip containing wells with pre-395 
dispensed reagents. The COVID-19 reagent contains biotinylated recombinant versions of the 396 
SARS-CoV-2 S-Protein RBD and trace amounts of N protein as antigens that bind IgG and IgM, 397 
respectively. The cut off values for both Pylon assays were determined using the mean of non-398 
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COVID-19 samples plus 6 Standard Deviations (SDs). The results of a sample are reported in the 399 
form of a cutoff index (COI) or an index value (IV), which were determined by the instrument 400 
readout of the test sample divided by instrument readout at cut off. 401 
 402 
ELISAs  403 
Validated ELISAs 43,44 to evaluate antibodies binding to SARS-CoV-2 RBD and additional RBDs 404 
were performed by coating of high-binding 96-half-well plates (Corning 3690) with 50 μl per well 405 
of a 1μg/ml protein solution in PBS overnight at 4 °C. Plates were washed 6 times with washing 406 
buffer (1× PBS with 0.05% Tween-20 (Sigma-Aldrich)) and incubated with 170 μl per well 407 
blocking buffer (1× PBS with 2% BSA and 0.05% Tween-20 (Sigma)) for 1 h at room temperature. 408 
Immediately after blocking, monoclonal antibodies or plasma samples were added in PBS and 409 
incubated for 1 h at room temperature. Plasma samples were assayed at a 1:67 starting dilution and 410 
7 additional threefold serial dilutions. Monoclonal antibodies were tested at 10 μg/ml starting 411 
concentration and 10 additional fourfold serial dilutions. Plates were washed 6 times with washing 412 
buffer and then incubated with anti-human IgG, IgM or IgA secondary antibody conjugated to 413 
horseradish peroxidase (HRP) (Jackson Immuno Research 109-036-088 109-035-129 and Sigma 414 
A0295) in blocking buffer at a 1:5,000 dilution (IgM and IgG) or 1:3,000 dilution (IgA). Plates 415 
were developed by addition of the HRP substrate, TMB (ThermoFisher) for 10 min (plasma 416 
samples)  or 4 minutes (monoclonal antibodies), then the developing reaction was stopped by 417 
adding 50 μl 1 M H2SO4 and absorbance was measured at 450 nm with an ELISA microplate 418 
reader (FluoStar Omega, BMG Labtech) with Omega and Omega MARS software for analysis. 419 
For plasma samples, a positive control (plasma from patient COV72, diluted 66.6-fold and seven 420 
additional threefold serial dilutions in PBS) was added to every assay plate for validation. The 421 
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average of its signal was used for normalization of all of the other values on the same plate with 422 
Excel software before calculating the area under the curve using Prism V8.4 (GraphPad). For 423 
monoclonal antibodies, the EC50 was determined using four-parameter nonlinear regression 424 
(GraphPad Prism V8.4).  425 
 426 
Expression of RBD proteins  427 
Mammalian expression vectors encoding the RBDs of SARS-CoV-2 (GenBank MN985325.1; S 428 
protein residues 319-539) and eight additional mutant RBD proteins (E484K, Q493R, R346S, 429 
N493K, N440K, V367F, A475V, S477N and V483A) with an N-terminal human IL-2 or Mu 430 
phosphatase signal peptide were previously described 45.  431 
 432 
SARS-CoV-2 pseudotyped reporter virus 433 
SARS-CoV-2 pseudotyped particles were generated as previously described 1,46. Briefly, 293T 434 
cells were transfected with pNL4-3DEnv-nanoluc and pSARS-CoV-2-SΔ19. For generation of 435 
RBD-mutant pseudoviruses, pSARS-CoV-2-S Δ19 carrying either of the following spike mutations 436 
was used instead of its wt counterpart: Q493R, R346S or E484G 47. Particles were harvested 48 437 
hpt, filtered and stored at -80°C. 438 
 439 
Pseudotyped virus neutralization assay 440 
Fourfold serially diluted plasma from COVID-19-convalescent individuals or monoclonal 441 
antibodies were incubated with SARS-CoV-2 pseudotyped virus for 1 h at 37 °C. The mixture was 442 
subsequently incubated with 293TAce2 cells for 48 h after which cells were washed with PBS and 443 
lysed with Luciferase Cell Culture Lysis 5× reagent (Promega). Nanoluc Luciferase activity in 444 
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lysates was measured using the Nano-Glo Luciferase Assay System (Promega) with the Glomax 445 
Navigator (Promega). The obtained relative luminescence units were normalized to those derived 446 
from cells infected with SARS-CoV-2 pseudotyped virus in the absence of plasma or monoclonal 447 
antibodies. The half-maximal inhibitory concentration for plasma (NT50) or monoclonal antibodies 448 
(IC50) was determined using four-parameter nonlinear regression (least squares regression method 449 
without weighting; constraints: top=1, bottom=0) (GraphPad Prism). 450 
 451 
Biotinylation of viral protein for use in flow cytometry 452 
Purified and Avi-tagged SARS-CoV-2 RBD was biotinylated using the Biotin-Protein Ligase-453 
BIRA kit according to manufacturer’s instructions (Avidity) as described before 1. Ovalbumin 454 
(Sigma, A5503-1G) was biotinylated using the EZ-Link Sulfo-NHS-LC-Biotinylation kit 455 
according to the manufacturer’s instructions (Thermo Scientific). Biotinylated ovalbumin was 456 
conjugated to streptavidin-BV711 (BD biosciences, 563262) and RBD to streptavidin-PE (BD 457 
Biosciences, 554061) and streptavidin-AF647 (Biolegend, 405237)1. 458 
 459 
Single-cell sorting by flow cytometry 460 
Single-cell sorting by flow cytometry was described previously 1. Briefly, peripheral blood 461 
mononuclear cells were enriched for B cells by negative selection using a pan-B-cell isolation kit 462 
according to the manufacturer’s instructions (Miltenyi Biotec, 130-101-638). The enriched B cells 463 
were incubated in FACS buffer (1× PBS, 2% FCS, 1 mM EDTA) with the following anti-human 464 
antibodies (all at 1:200 dilution): anti-CD20-PECy7 (BD Biosciences, 335793), anti-CD3-APC-465 
eFluro 780 (Invitrogen, 47-0037-41), anti-CD8-APC-eFluor 780 (Invitrogen, 47-0086-42), anti-466 
CD16-APC-eFluor 780 (Invitrogen, 47-0168-41), anti-CD14-APC-eFluor 780 (Invitrogen, 47-467 
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0149-42), as well as Zombie NIR (BioLegend, 423105) and fluorophore-labelled RBD and 468 
ovalbumin (Ova) for 30 min on ice. Single CD3−CD8−CD14−CD16−CD20+Ova−RBD-469 
PE+RBD-AF647+ B cells were sorted into individual wells of 96-well plates containing 4 μl of 470 
lysis buffer (0.5× PBS, 10 mM DTT, 3,000 units/ml RNasin Ribonuclease Inhibitors (Promega, 471 
N2615) per well using a FACS Aria III and FACSDiva software (Becton Dickinson) for 472 
acquisition and FlowJo for analysis. The sorted cells were frozen on dry ice, and then stored at 473 
−80 °C or immediately used for subsequent RNA reverse transcription.  474 
 475 
Antibody sequencing, cloning and expression 476 
Antibodies were identified and sequenced as described previously 1. In brief, RNA from single 477 
cells was reverse-transcribed (SuperScript III Reverse Transcriptase, Invitrogen, 18080-044) and 478 
the cDNA stored at −20 °C or used for subsequent amplification of the variable IGH, IGL and IGK 479 
genes by nested PCR and Sanger sequencing. Sequence analysis was performed using MacVector. 480 
Amplicons from the first PCR reaction were used as templates for sequence- and ligation-481 
independent cloning into antibody expression vectors. Recombinant monoclonal antibodies and 482 
Fabs were produced and purified as previously described 1. 483 
 484 
Computational analyses of antibody sequences 485 
Antibody sequences were trimmed based on quality and annotated using Igblastn v.1.14. with 486 
IMGT domain delineation system. Annotation was performed systematically using Change-O 487 
toolkit v.0.4.540 48. Heavy and light chains derived from the same cell were paired, and clonotypes 488 
were assigned based on their V and J genes using in-house R and Perl scripts (Extended data Fig.4). 489 
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All scripts and the data used to process antibody sequences are publicly available on GitHub 490 
(https://github.com/stratust/igpipeline). 491 
 492 
The frequency distributions of human V genes in anti-SARS-CoV-2 antibodies from this study 493 
was compared to 131,284,220 IgH and IgL sequences generated by 49 and downloaded from cAb-494 
Rep50, a database of human shared BCR clonotypes available at https://cab-495 
rep.c2b2.columbia.edu/. Based on the 82 distinct V genes that make up the 1703 analyzed 496 
sequences from Ig repertoire of the three patients present in this study, we selected the IgH and 497 
IgL sequences from the database that are partially coded by the same V genes and counted them 498 
according to the constant region. The frequencies shown in (Fig. S4) are relative to the source and 499 
isotype analyzed. We used the two-sided binomial test to check whether the number of sequences 500 
belonging to a specific IgHV or IgLV gene in the repertoire is different according to the frequency 501 
of the same IgV gene in the database. Adjusted p-values were calculated using the false discovery 502 
rate (FDR) correction. Significant differences are denoted with stars. 503 
 504 
Nucleotide somatic hypermutation and CDR3 length were determined using in-house R and Perl 505 
scripts. For somatic hypermutations, IGHV and IGLV nucleotide sequences were aligned against 506 
their closest germlines using Igblastn and the number of differences were considered nucleotide 507 
mutations. The average mutations for V genes was calculated by dividing the sum of all nucleotide 508 
mutations across all patients by the number of sequences used for the analysis. To calculate the 509 
GRAVY scores of hydrophobicity 51 we used Guy H.R. Hydrophobicity scale based on free energy 510 
of transfer (kcal/mole) 52 implemented by the R package Peptides (the Comprehensive R Archive 511 
Network repository; https://journal.r-project.org/archive/2015/RJ-2015-001/RJ-2015-001.pdf). 512 
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We used 532 heavy chain CDR3 amino acid sequences from this study and 22,654,256 IGH CDR3 513 
sequences from the public database of memory B cell receptor sequences 53. The Shapiro–Wilk 514 
test was used to determine whether the GRAVY scores are normally distributed. The GRAVY 515 
scores from all 532 IGH CDR3 amino acid sequences from this study were used to perform the 516 
test and 5,000 GRAVY scores of the sequences from the public database were randomly selected. 517 
The Shapiro–Wilk P values were 6.896 × 10−3 and 2.217 × 10−6 for sequences from this study 518 
and the public database, respectively, indicating that the data were not normally distributed. 519 
Therefore, we used the Wilcoxon nonparametric test to compare the samples, which indicated a 520 
difference in hydrophobicity distribution (P = 5 × 10−6) (Extended data Fig.7). 521 
 522 
Heatmap of log2 relative fold change in EC50 against the indicated RBD mutants for antibody 523 
clonal pairs obtained at 1.3 and 6.2 months (Fig.3e and Extended data Fig. 8k) was created with R 524 
pheatmap package (https://github.com/raivokolde/pheatmap) using Euclidean distance and 525 
Ward.2 clustering method. 526 
 527 
Biopsies and Immunofluorescence 528 
Endoscopically obtained mucosal biopsies were formalin fixed and paraffin embedded. Sections 529 
(5µm) were cut, dewaxed in xylene, and rehydrated in graded alcohol and phosphate-buffered 530 
saline (PBS). Heat-induced epitope retrieval was performed in target retrieval solution (Dako, 531 
S1699) using a commercial pressure cooker. Slides were then cooled to room temperature, washed 532 
in PBS and permeabilized for 30 minutes in 0.1% tritonX-100 in PBS. Non-specific binding was 533 
blocked with 10% goat serum (Invitrogen, 50062Z) for 1 hour at room temperature. Sections were 534 
then incubated with a combination of primary antibodies diluted in blocking solution overnight at 535 
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4°C. Slides were washed 3 times in PBS and then incubated in secondary antibody and 4′,6-536 
diamidino-2-phenylindole (1ug/mL) for 1 hour at room temperature. Sections were washed in PBS 537 
3 times and then mounted with Fluoromount-G (Electron Microscopy Sciences, 1798425). 538 
Controls included, omitting primary antibody (no primary 995 control), or substituting primary 539 
antibodies with non-reactive antibodies of the same isotype (isotype control). A Nikon Eclipse Ni 540 
microscope and digital SLR camera (Nikon, DS-Qi2) was used to visualize and image the tissue.  541 
 542 
The antibody used to stain sections for N protein was raised in rabbits against SARS-CoV N and 543 
is cross-reactive with SARS-CoV-2 N protein 54. 544 
 545 
Antigen  Clone Vendor Catalogue 
number 
Host 
species 
Conjugate  Dilution 
ACE2 Polyclonal 
 
Abcam ab15348 
 
rabbit unconjugated 1:1000 
EPCAM SPM491 
 
GeneTex GTX34693 
 
mouse unconjugated 1:100 
SARS-CoV-2 
nucleocapsid 
Polyclonal 
 
Spiegel, M. 
et al. 54 
N/A rabbit unconjugated 1:2000 
No known 
specificity 
(isotype control) 
Polyclonal 
 
Abcam ab37415 
 
rabbit unconjugated variable 
Yeast GAL4 
(isotype control) 
15-6E10A7 
 
Abcam ab170190 
 
mouse unconjugated variable 
Mouse IgG H&L 
 
Polyclonal 
 
Abcam ab150116 
 
goat Alexa Fluor 594 
 
1:1000 
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Rabbit IgG H&L 
 
Polyclonal 
 
Abcam ab150077 
 
goat Alexa Fluor 488 
 
1:1000 
 546 
SARS-CoV-2 PCR (intestinal biopsies) 547 
To determine if SARS-CoV-2 RNA is present in the gastrointestinal tract we isolated 548 
RNA from endoscopically obtained mucosal biopsies using Direct-zol miniprep kit (Zymo 549 
research, Cat. No. R2050). Reverse transcribed cDNA was amplified using 2019-nCov Ruo Kit 550 
(IDT) to detect viral nucleocapsid genomic RNA.  Amplification of sub-genomic nucleocapsid 551 
RNA was done using following primers and probe: sgLeadSARSCov2_F  5’- 552 
CGATCTCTTGTAGATCTGTTCTC -3’26, wtN_R4 5’ – GGTGAACCAAGACGCAGTAT – 3’, 553 
wtN_P4  5’ – /56-FAM/TAACCAGAA/ZEN/TGGAGAACGCAGTGGG/3IABkFQ/ – 3’. 554 
Quantitative PCR was performed using QuantTect probe PCR kit (Qiagen, Cat. No. 204345) under 555 
following conditions: 95 15’, 95°C 15 sec, 60°C 1 min using the Applied Biosystem QuantStudio 556 
6 Flex Real-Time PCR System. Viral RNA was considered detected if the cycle threshold (Ct) for 557 
viral primers/probes was <40. Samples from positive wells were column purified and presence of 558 
N1 sequences additionally verified by Sanger sequencing. 559 
 560 
Electron Microscopy and Dual-Axis Tomography  561 
Tissues samples were fixed with 3% glutaraldehyde to meet biosafety requirements. Tissues were 562 
rinsed with cold 0.1M sodium cacodylate trihydrate + 5% sucrose and further dissected to block 563 
sizes sufficient for embedding and sectioning. Tissues were postfixed for 1 h with cold 2% osmium 564 
tetroxide in cacodylate buffer, en bloc stained with 1% aqueous uranyl acetate, dehydrated with 565 
acetone and embedded in Epon-Araldite resin (Electron Microscopy Sciences). Samples were flat-566 
embedded between two Teflon-coated glass microscope slides and the resin polymerized at 60 °C 567 
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for 24 h. Embedded tissue blocks were observed by light microscopy to ascertain preservation 568 
quality and select regions of interest (i.e., apical epithelium). Blocks were extracted with a scalpel 569 
and glued to plastic sectioning stubs prior to sectioning. Semi-thin (150 nm) serial sections were 570 
cut with a UC6 ultramicrotome (Leica Microsystems) using a diamond knife (Diatome, Ltd. 571 
Switzerland). Sections were placed on formvar-coated copper-rhodium slot grids (Electron 572 
Microscopy Sciences) and stained with 3% uranyl acetate and lead citrate. Colloidal gold particles 573 
(10 nm) were placed on both surfaces of the grids to serve as fiducial markers for tomographic 574 
image alignment. Grids were placed in a dual-axis tomography holder (Model 2010, E.A. 575 
Fischione Instruments, Export PA) and imaged with a Tecnai G2 T12 transmission electron 576 
microscope (120 KeV; ThermoFisher Scientific). Images were recorded with a 2k x 2k CCD 577 
camera (XP1000; Gatan, Pleasonton, CA). Tomographic tilt series and large-area montages were 578 
acquired automatically using the SerialEM software package  55. For dual-axis tomography, images 579 
were collected at 1° intervals as samples were tilted +/- 62°. The grid was then rotated 90° and a 580 
second tilt-series was acquired about the orthogonal axis. Tomograms were calculated, analyzed 581 
and modeled using the IMOD software package 56,57 on MacPro and iMac Pro computers (Apple, 582 
Inc).  583 
 584 
Presumptive SARS-CoV-2 virions were identified from tomographic reconstructions of tissue 585 
samples by observing structures resembling virions described in cryo-electron tomography studies 586 
of purified SARS-CoV-2 and SARS-CoV-2 in infected cells 58-61. We used the following criteria 587 
for SARS-CoV-2 virion identification in tissues: (i) Structures that were spherical in 3D and not 588 
continuous with other adjacent structures with ~60-120 nM diameters, (ii) Spherical structures 589 
with densities corresponding to a distinct membrane bilayer, internal puncta consistent with 590 
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ribonucleoproteins 58, and densities corresponding to surface spikes on the external peripheries of 591 
the spheres. 592 
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Extended Data Figures 632 
 633 
Extended Data Fig. 1: Clinical correlates of plasma antibody titres. 634 
a, Normalized AUC anti-RBD IgG titres at 1.3 months for participants with (n=38) or without 635 
(n=49) persistent post-acute symptoms. b, Normalized AUC anti-RBD IgG titres at 6.2 months for 636 
participants with (n=38) or without (n=49) persistent post-acute symptoms. c, Normalized AUC 637 
anti-RBD IgM titres at 1.3 months for participants with (n=38) or without (n=49) persistent post-638 
acute symptoms. d, Normalized AUC anti-RBD IgM titres at 6.2 months for participants with 639 
(n=38) or without (n=49) persistent post-acute symptoms. e, Normalized AUC anti-RBD IgA titres 640 
at 1.3 months for participants with (n=38) or without (n=49) persistent post-acute symptoms. f, 641 
Normalized AUC anti-RBD IgA titres at 6.2 months for participants with (n=38) or without (n=49) 642 
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persistent post-acute symptoms. g, COI values of anti-N total Ig titres at 1.3 months for participants 643 
with (n=38) or without (n=49) persistent post-acute symptoms. h, COI values of anti-N total Ig 644 
titres at 6.2 months for participants with (n=38) or without (n=49) persistent post-acute symptoms. 645 
i, IV values of anti-RBD IgG titres at 1.3 months for participants with (n=38) or without (n=49) 646 
persistent post-acute symptoms. j, IV values of anti-RBD IgG titres at 6.2 months for participants 647 
with (n=38) or without (n=49) persistent post-acute symptoms. k, NT50 values at 1.3 months for 648 
participants with (n=38) or without (n=49) persistent post-acute symptoms. l, NT50 values at 6.2 649 
months for participants with (n=38) or without (n=49) persistent post-acute symptoms. m, Age in 650 
years for participants with (n=38) or without (n=49) persistent post-acute symptoms. n, Severity 651 
of acute infection as assessed by the WHO Ordinal Clinical Progression/Improvement Scale for 652 
participants with (n=38) or without (n=49) persistent post-acute symptoms. o, Duration of 653 
Symptoms during acute infection for participants with (n=38) or without (n=49) persistent post-654 
acute symptoms. Horizontal bars indicate median values. Statistical significance was determined 655 
using Mann–Whitney U-tests. 656 
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 657 
Extended Data Fig. 2: Correlations of plasma antibody measurements.  658 
a, Normalized AUC for IgG anti-RBD plotted against Pylon IgG anti-RBD index values at 1.3 659 
months. b, Normalized AUC for IgG anti-RBD plotted against Pylon IgG anti-RBD index values 660 
at 6.2 months. c, Normalized AUC for IgM anti-RBD plotted against Pylon IgM anti-RBD index 661 
values at 1.3 months. d, Normalized AUC for IgM anti-RBD plotted against Pylon IgM anti-RBD 662 
index values at 6.2 months. e, Normalized AUC for IgM anti-RBD at 6.2 months plotted against 663 
IgM anti-RBD at 1.3 months. f, Normalized AUC for IgG anti-RBD at 6.2 months plotted against 664 
IgG anti-RBD at 1.3 months. g, Normalized AUC for IgA anti-RBD at 6.2 months plotted against 665 
IgA anti-RBD at 1.3 months. h, COI values for anti-N total Ig titres at 6.2 months plotted against 666 
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anti-N total Ig titres at 1.3 months. i, Anti-RBD IgG titres at 1.3 months plotted against anti-N total 667 
Ig titres at 1.3 months. j, Anti-RBD IgG titres at 6.2 months plotted against anti-N total Ig titres at 668 
6.2 months. k, Anti-RBD IgM titres at 1.3 months plotted against anti-N total Ig titres at 1.3 669 
months. l, Anti-RBD IgM titres at 6.2 months plotted against anti-N total Ig titres at 6.2 months. 670 
m, Anti-RBD IgA titres at 1.3 months plotted against anti-N total Ig titres at 1.3 months. l, Anti-671 
RBD IgA titres at 6.2 months plotted against anti-N total Ig titres at 6.2 months. o, NT50 values at 672 
1.3 months plotted against anti-RBD IgG titres at 1.3 months. p, NT50 values at 6.2 months plotted 673 
against anti-RBD IgG titres at 6.2 months. The r and p values were determined by two-tailed 674 
Spearman’s correlations. 675 
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 676 
Extended Data Fig. 3: Flow cytometry. 677 
a, Gating strategy used for cell sorting. Gating was on singlets that were CD20+ and 678 
CD3−CD8−CD16−Ova−. Sorted cells were RBD-PE+ and RBD-AF647+. b, Flow cytometry 679 
showing the percentage of RBD-double positive memory B cells from month 1.3 or month 6 post-680 
infection in 21 randomly selected patients.  681 
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 682 
Extended Data Fig. 4: Frequency distributions of human V genes.  683 
a, Two-sided binomial tests were used to compare the frequency distributions of human V genes 684 
of anti-SARS-CoV-2 antibodies from donors at 1.3 months to 6.2 months 1. b, Two-sided binomial 685 
tests were used to compared the frequency distributions of human V genes of anti-SARS-CoV-2 686 
antibodies from this study to sequence from C. Soto et al. 49.  687 
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 688 
Extended Data Fig. 5: Circos plots and IgG positive RBD specific B cells 689 
a, Sequences from all six individuals with clonal relationships depicted as in Figure 2d. 690 
Interconnecting lines indicate the relationship between antibodies that share V and J gene segment 691 
sequences at both IGH and IGL. Purple, green and grey lines connect related clones, clones and 692 
singles, and singles to each other, respectively. b, For each patient, the number of IgG heavy chain 693 
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sequences (black) analyzed from six individuals at month 1.3 (left panel) or month 6.2 post-694 
infection (right panel). The number in the inner circle indicates the number of cells that was sorted 695 
for each individual denoted above the circle. c, The same as b but showing the all 6 patients 696 
combined data. d, The comparison of the percentage of IgG positive B cells from six individuals 697 
at month 1.3 or month 6.2 post-infection. The horizontal bars indicate the mean. Statistical 698 
significance was determined using paired t test. 699 
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Extended Data Fig. 6: Analysis of antibody somatic hypermutation of persisting clones.  701 
Number of somatic nucleotide mutations in both the IGVH and IGVL of persisting clones found 702 
at month 1.3 (solid circles) and month 6.2 time points (open circles) in patients (a) COV21, (b) 703 
COV47, (c) COV57, (d) COV72, (e) COV96, and (f) COV107. The VH and VL gene usage of 704 
each clonal expansion is indicated above the graphs, or are indicated as “Singlets” if the persisting 705 
sequence was isolated only once at both time points. Connecting line indicates the SHM of the 706 
clonal pairs that were expressed as a recombinant mAbs.  707 
  708 
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 709 
Extended Data Fig. 7: Analysis of CDR3 length and hydrophobicity. 710 
a, For each individual, the number of the amino acid length of the CDR3s at the IGVH and IGVL 711 
is shown. The horizontal bars indicate the mean. The number of antibody sequences (IGVH and 712 
IGVL) evaluated for each participant are n = 90 (COV21), n = 78 (COV47), n = 53 (COV57), n = 713 
87 (COV72), n = 104 (COV96), n = 120 (COV107).  Right panel show all antibodies combined (n 714 
= 532 for both IGVH and IGVL).  b, Distribution of the hydrophobicity GRAVY scores at the 715 
IGH CDR3 in antibody sequences from this study compared to a public database (see Methods for 716 
statistical analysis). The box limits are at the lower and upper quartiles, the centre line indicates 717 
the median, the whiskers are 1.5× interquartile range and the dots represent outliers.   718 
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Extended Data Fig. 8: ELISA of wt/mutant RBD for mAbs.  720 
a, EC50 values for binding to wild type RBD of shared singlets and shared clones of mAbs 721 
obtained at the initial 1.3 and 6.2 months follow-up visit, divided by patient. Lines connect shared 722 
singlets/clones. mAbs with improved EC50 at 6.2 months follow-up visit are highlighted in green, 723 
remaining mAbs are shown in black. Statistical significance was determined using Wilcoxon 724 
matched-pairs signed rank test. b-j, Graphs show ELISA binding curves for different antibodies 725 
obtained at 1.3 months (dashed lines) and their clonal relatives obtained after 6.2 months (solid 726 
lines) binding to wild type, R346S, E484K, Q493R, N439K, N440K, A475V, S477N, V483A and 727 
V367F RBDs (colors as indicated). Antibody IDs of pairs as indicated on top of panels (1.3m / 728 
6.2m). k, Heat map shows log2 relative fold change in EC50 against the indicated RBD mutants 729 
for 52 antibody clonal pairs obtained at 1.3 (black) and 6.2 months (red). The clonal and participant 730 
origin for each antibody pair is indicated above. 731 
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 732 
Extended Data Fig. 9: neutralization of wt/mutant RBD pseudotypes by mAbs.  733 
a, IC50 values of shared singlets and shared clones of mAbs obtained at the initial 1.3- and 6.2-734 
months follow-up visit, divided by patient. Lines connect shared singlets/clones. mAbs with 735 
undetectable IC50 at 1.3 months are plotted at 10 µg/ml and are highlighted in red, mAbs with 736 
improved IC50 at 6.2 months follow-up visit are highlighted in green, remaining mAbs are shown 737 
in black. Statistical significance was determined using Wilcoxon matched-pairs signed rank test. 738 
b-f, The normalized relative luminescence values for cell lysates of 293TAce2 cells 48 hpi with 739 
SARS-CoV-2 pseudovirus harboring wt RBD or RBD-mutants (wt, Q493R, E484G and R346S 740 
RBD shown in black, red, green and blue, respectively) in the presence of increasing 741 
concentrations of mAbs obtained at the 1.3 months initial visit (1.3m, dashed lines) and their shared 742 
clones/singlets at the 6.2 follow-up visit (6.2m, continuous lines). Antibody IDs as indicated. 743 
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 744 
Extended Data Fig. 10: C51 alignment and binding projection 745 
a, VH and VL amino acid sequence alignment of C144 and derivative antibodies C051, C052, 746 
C053 and C054. Germline-encoded residues are highlighted in green. Residues in the proximity 747 
of RBD-binding C144 paratope are highlighted in red.  748 
b-e, Surface representation of two adjacent “down” RBDs (RBDA and RBDB) on a spike trimer 749 
with the C144 epitope on the RBDs highlighted in cyan and positions of amino acid mutations that 750 
accumulated in b, C052. c, C053 and d, C054 compared to the parent antibody C144 highlighted 751 
as stick side chains on a Ca atom representation. The C052, C053 and C054 interactions with two 752 
RBDs was modeled based on a cryo-EM structure of C144 Fab bound to spike trimer 16. 753 
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 754 
Extended Data Fig. 11: SARS-CoV-2 antigen in human enterocytes in the gastrointestinal 755 
tract 3 months post COVID-19 756 
Immunofluorescence images of human gastrointestinal tissue are shown. Staining is for EPCAM 757 
(red), DAPI (blue) and SARS-CoV-2 nucleocapsid (green) Samples are derived from intestinal 758 
biopsies in the gastrointestinal tract as indicated (A-E). (A-D) are biopsies from participant CGI-759 
088 (Supplementary Table 7) taken 92 days post COVID-19 symptom onset. (E) is a biopsy 27 760 
months prior to COVID-19 symptom onset from the same participant CGI-088. Arrows indicate 761 
enterocytes with detectable SARS-CoV-2 antigen. Isotype and no primary controls for each tissue 762 
are shown in the last two columns. White scale bar corresponds to 100 μm. 763 
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 764 
Extended Data Fig. 12: SARS-CoV-2 antigen is detectable in different intestinal segments in 765 
multiple COVID-19 convalescent individuals 766 
a, Immunofluorescence (IF) images of biopsy samples in the gastrointestinal tract in different 767 
individuals are shown. Staining is for EPCAM (red), DAPI (blue) and SARS-CoV-2 nucleocapsid 768 
(green). Samples are derived from intestinal biopsies from 4 participants (CGI089, CGI092, 769 
CGI100 and CGI106) taken at least 3 months after COVID-19 infection. Arrows indicate 770 
enterocytes with detectable SARS-CoV-2 antigen. White scale bar corresponds to 100 μm. b, 771 
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Quantification of SARS-CoV-2 positive cells by immunofluorescence. The number of cells 772 
staining positive for the nucleocapsid protein (N) of SARS-CoV-2 per mm2 of intestinal epithelium 773 
is shown. The graphs show biopsy samples from the indicated individuals of the duodenum (left) 774 
and terminal ileum (right), respectively. Black dots represent the number of available biopsy 775 
specimen for each individual from the respective intestinal segment. Boxes represent median 776 
values and whiskers the 95 % CI. 777 
 778 
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Extended Data Fig. 13: Pre-COVID-19 historic control individuals show no detectable 779 
SARS-CoV-2 antigen by immunofluorescence 780 
Immunofluorescence images of biopsy samples in the gastrointestinal tract obtained from 10 781 
different individuals between January 2018 and October 2019 are shown. Staining is for EPCAM 782 
(red), DAPI (blue) and SARS-CoV-2 nucleocapsid (green). White scale bar corresponds to 100 783 
μm. 784 
  785 
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 
The copyright holder for this preprintthis version posted November 5, 2020. ; https://doi.org/10.1101/2020.11.03.367391doi: bioRxiv preprint 
 54 
Supplementary Tables 786 
 787 
Supplementary Table 1: Cohort summary 788 
 789 
Supplementary Table 2: Individual participant characteristics 790 
Table S1.  Cohort characteristics
Sex n IgG (T1) IgG (T2)
IgM 
(T1)
IgM 
(T2)
IgA 
(T1)
IgA 
(T2)
total 
Ig (T1)
total 
Ig (T2) (T1) (T2)
44.5 39 190 148 2 25/52
(24-76) (21-63) (165-211) (119-178) (0-6) (48.1 %)
45 36 192 154 2 13/35
(26-73) (17-67) (168-223) (122-179 (0-5) (37.1 %)
Sx = Symptoms
¶ = WHO Ordinal Scale for Clinical Improvement, COVID-19 Trial Design Synopsis
† = Persistent fatigue, dyspnea, athletic deficit, or ≥ 3 other solicited symptoms beyond 6 weeks from Sx onset
Reported data are median (range) unless stated otherwise
78
87
Neutralization 
(NT50)
6834
1502
1459
53.9 649
56.8 297
RBD (AUC)
1411 1218
Female 35 8884 2358 59.81235 1083
Age 
(years)
Sx onset
 to initial visit 
(T1)
 N (COI)
Male 52 11632 2811 47.86697
Sx onset to 
follow-up visit 
(T2)
Time 
between 
visits
Temporal dynamics (days)
Post-acute Sx 
persistence † 
ELISA binding
Acute disease 
severity by 
WHO (0-8) ¶
 
SI Table 1. Individual participant characteristics
ID
Age 
(years) Sex Race IgG (T1) IgG (T2) IgM (T1) IgM (T2) IgA (T1) IgA (T2) IgG (T1) IgG (T2) IgM (T1) IgM (T2)
total Ig 
(T1)
total Ig 
(T2)
(T1) (T2)
7 40 M White Non-Hispanic 11 30 181 151 0 2 Y 11981 9545 6524 1516 1479 1344 34 18 3.6 0.31 56 171 2730 192
8 37 M White Non-Hispanic 3 57 205 148 0 2 Y 9010 7653 1998 1153 1342 1380 6.9 4.9 0.27 0.26 43 16 151 39
9 35 F White Non-Hispanic 12 53 201 148 0 2 Y 18953 12848 2963 1753 989 1227 27 23 1.1 0.49 174 187 306 295
20 26 F White Non-Hispanic 2 17 191 174 1 2 N 4134 8690 1976 1228 1018 1314 1.5 13 0.36 0.25 1 4 50 172
21 54 M White Hispanic 11 27 200 173 1 2 Y 36389 20744 14506 1242 2855 1914 127 59 4.4 0.23 82 159 5053 561
24 34 M White Non-Hispanic 15 30 175 145 1 1 N 5736 3803 2715 1150 927 1101 2.9 0.93 0.34 0.2 6 17 281 10
27 28 M White Non-Hispanic 9 32 210 178 1 1 Y 9283 5312 2182 1943 2182 1943 13 4.5 0.35 0.21 88 168 739 86
31 51 M White Non-Hispanic 9 33 183 150 0 2 Y 3212 3705 1272 903 906 913 1.3 1.5 0.22 0.15 35 41 192 18
38 57 F White Non-Hispanic 10 38 211 173 0 2 N 13718 12760 2009 1249 2902 3198 11 59 0.24 0.35 49 35 519 832
40 44 M White Non-Hispanic 7 23 195 172 0 2 N 5291 6467 1792 1161 1481 1501 0.6 0.6 0.33 0.15 3 12 64 10
46 39 M White Non-Hispanic 8 30 174 144 0 2 Y 4799 4416 2247 1315 1055 1153 3 2.2 0.24 0.17 51 141 59 21
47 43 F White Non-Hispanic 11 33 177 144 0 2 Y 17581 9284 9749 1914 1586 851 43 16 1.2 0.21 103 101 10433 349
48 37 F White Non-Hispanic 7 21 174 153 0 2 N 3265 3681 2358 1952 802 898 2.8 3.9 0.27 0.23 2 10 173 22
55 36 M White Non-Hispanic 3 49 210 161 0 2 N 12982 6419 2515 1487 2213 1466 16 3.3 0.27 0.19 85 17 186 10
57 66 M White Non-Hispanic 6 21 180 159 4 2 N 9108 4987 9199 2622 954 884 23 4.6 1.7 0.35 19 128 2049 45
71 45 F White Non-Hispanic 12 48 202 154 0 2 Y 5207 4559 1606 998 723 860 3.5 6.6 0.14 0.33 21 33 112 65
72 42 M White Non-Hispanic 16 35 188 153 1 2 Y 24822 10485 24034 2095 4887 2407 N/A N/A N/A N/A N/A N/A 3138 81
75 46 F White Non-Hispanic 10 36 212 176 0 1 N 5083 3811 1386 1459 1386 1459 7.2 2.1 0.36 0.2 71 74 271 36
76 49 F White Non-Hispanic 28 34 204 170 0 1 Y 8354 5632 1697 1299 1320 886 5.1 0.67 0.23 0.22 3 2 220 10
82** 46 M N/A Non-Hispanic 0 N/A N/A 163 0 1 N 6472 5187 2667 3094 1125 846 N/A N/A N/A N/A N/A N/A 131 20
88 41 M White Non-Hispanic 7 23 180 157 1 1 N 8263 6730 1789 2276 1546 903 4.7 9.3 0.56 0.31 7 186 425 56
95 44 M White Non-Hispanic 9 36 204 168 1 2 Y 14380 7894 2709 1703 1250 1023 18 7.2 0.42 0.12 136 235 962 155
96 48 F White Non-Hispanic 9 30 194 164 0 1 N 24147 15675 3959 1498 1099 965 N/A N/A N/A N/A N/A N/A 928 206
98 35 F White Non-Hispanic 2 24 203 179 0 2 N 8275 7190 2495 2417 2495 2417 15 6.9 0.7 0.65 72 55 249 53
99 36 F White Non-Hispanic 13 29 204 175 0 2 N 12764 6017 2693 2390 2693 2390 24 5.3 0.41 0.34 46 12 1128 163
107 53 F White Non-Hispanic 10 29 202 173 0 2 Y 7967 6298 1560 1025 915 850 3.8 6.3 0.49 0.18 64 76 297 87
114 30 F White Non-Hispanic 15 36 195 159 0 2 Y 5979 5654 1163 912 898 940 N/A N/A N/A N/A N/A N/A 114 32
115 65 F White Non-Hispanic 20 41 188 147 0 2 N 26997 11600 19944 2081 991 890 63 22 2.9 0.27 116 157 1128 432
119 56 M White Non-Hispanic 13 48 207 159 0 1 N 12155 6663 7000 1533 2152 1822 13 4.2 14 1.1 20 23 650 35
120 56 F White Non-Hispanic 26 48 207 159 0 1 N 6096 6292 2310 1091 856 1045 5.5 2.7 0.33 0.14 10 9 101 10
123 26 M White Non-Hispanic 12 34 191 157 0 2 Y 5977 6228 2722 1880 1127 1357 2.1 0.67 0.21 0.15 4 2 76 10
125 51 F White Non-Hispanic 10 26 168 142 0 1 N 4498 4271 2234 1361 684 807 1.8 1.1 1 0.19 4 2 127 10
131 39 M White Non-Hispanic 5 25 191 166 0 0 N 4285 3911 1318 943 1201 1166 0.27 0.93 0.35 0.26 1 3 50 14
132 36 M White Non-Hispanic 10 50 193 143 0 0 N 12506 8783 8532 4822 1068 1070 10 9.8 0.81 0.26 161 149 521 200
134 27 F White Non-Hispanic 16 22 171 149 0 0 N 8884 6818 7472 2068 1057 982 4.1 3.7 2.1 0.37 15 6 2701 263
135 62 F White Non-Hispanic 8 31 190 159 0 2 N 9301 8386 3157 888 1256 952 9.9 16 0.77 0.21 50 81 350 441
140 63 F White Non-Hispanic 28 47 223 176 0 1 N 6181 4957 1235 1061 1235 1061 3.5 2.2 0.22 0.12 39 14 52 13
149 41 M White Non-Hispanic 17 28 173 145 1 2 N 6275 3875 1422 1073 1058 842 10 3.4 0.48 0.21 69 151 495 28
154 68 M Asian Non-Hispanic 16 30 196 166 3 2 Y 25056 13409 5544 1169 2072 1205 57 16 2.9 0.18 13 23 928 65
157 50 M White Non-Hispanic 10 32 179 147 0 1 N 11979 8751 11125 2370 1969 1374 15 7.9 5.4 0.71 67 89 742 190
172 38 F White Non-Hispanic 8 22 182 160 1 2 N 10507 6124 4007 1339 3230 1244 5.2 5.1 0.85 0.21 14 102 301 157
173 47 M White Non-Hispanic 5 53 185 132 0 2 N 9127 5004 12194 1660 1162 979 2.5 2.8 7.3 0.59 149 143 647 176
178 26 F White Non-Hispanic 6 24 190 166 1 1 N 4316 3757 1394 1373 1351 1222 1.2 0.73 0.43 0.49 2 3 10 10
186 38 F N/A N/A 8 33 189 156 0 1 N 7427 4850 1687 960 1085 815 10 5 0.41 0.29 64 32 297 73
190* 54 F White Non-Hispanic 18 63 190 127 0 4 Y 16156 10408 4567 1664 1207 1107 43 18 0.9 0.42 102 81 598 165
192* 47 F White Non-Hispanic 44 62 190 128 1 3 Y 13879 9000 5894 1525 1819 1598 30 22 0.68 0.38 106 145 608 409
195 24 M White Non-Hispanic 18 42 191 149 0 2 N 14242 7933 3954 2055 1227 978 22 6.9 1.5 0.24 15 31 1315 106
201 50 M White Non-Hispanic 15 33 185 152 1 2 N 26093 11284 6230 1635 3374 1477 131 48 3.3 0.23 34 69 3897 741
222 28 M Asian Non-Hispanic 11 37 173 136 1 2 N 14063 6930 1132 723 2841 1612 7.9 2.7 0.37 0.18 14 17 865 50
229 45 M White Non-Hispanic 10 63 203 140 1 2 N 14677 8054 5507 1606 1066 1141 31 19 0.49 0.25 146 191 1273 135
230 50 M White Non-Hispanic 18 33 190 157 0 2 Y 5605 5015 1300 1868 1059 1130 1.8 1.5 0.19 0.17 6 10 382 375
232 38 F White Non-Hispanic 13 43 197 154 1 2 N 8127 15997 1948 2352 1335 1362 N/A N/A N/A N/A N/A N/A 147 633
233 55 M White Non-Hispanic 20 41 206 165 0 2 N 6897 6940 1917 1211 1066 1065 8.3 4.3 0.27 0.16 3 9 173 11
241 36 M White Non-Hispanic 12 30 202 172 1 2 N 8912 5749 7327 1446 2562 2195 3.3 0.8 1.4 0.38 69 18 923 118
256 63 F White Non-Hispanic 27 42 217 175 0 2 Y 10574 6500 1886 1533 1886 1533 7.7 6.4 0.34 0.17 65 27 142 31
287 47 M White Non-Hispanic 11 23 165 142 0 1 N 7442 4357 2873 1211 910 928 9.3 3.9 0.77 0.41 15 15 240 38
310 34 F White Non-Hispanic 17 35 185 150 0 2 Y 26782 15634 1554 1023 1435 1083 47 15 0.27 0.31 51 137 485 153
314 46 M White Non-Hispanic 11 43 184 141 0 2 Y 12475 7247 2431 1273 854 811 38 14 0.89 0.2 131 198 667 297
315 29 F White Non-Hispanic 15 42 190 148 0 1 N 18570 13153 2528 2022 1252 1083 55 21 0.75 0.31 135 58 376 179
319 50 M White Non-Hispanic 5 38 180 142 1 2 N 7614 4736 2215 762.1 1575 1174 6.9 3.9 0.26 0.16 27 12 241 74
323 39 F White Non-Hispanic 7 45 185 140 0 2 N 4220 5152 2930 1547 888 931 0.93 0.67 0.33 0.34 4 1 51 20
325 52 M White Non-Hispanic 16 38 192 154 0 2 Y 26673 12400 16598 4879 2703 1464 54 14 14 3 50 56 1603 229
328 54 F White Non-Hispanic 22 62 203 141 0 2 N 8118 7073 1216 1268 1216 1268 7.5 5.5 0.29 0.21 99 81 94 66
352 44 M White Non-Hispanic 16 43 197 154 0 2 N 19958 6525 5585 1064 2614 1731 43 11 0.84 0.22 17 16 519 33
353 60 M White Non-Hispanic 14 49 186 137 0 2 Y 23981 13736 6807 2062 9230 3637 58 20 0.83 0.22 68 51 855 222
393* 69 M White Non-Hispanic 23 54 187 133 0 5 N 8729 5150 13320 1974 1075 892 14 6.1 2.5 0.27 13 51 715 144
394 48 F Multiple Hispanic 7 67 200 133 2 2 N 22856 12823 6178 1909 1009 1131 96 35 1.1 0.34 59 69 1281 282
401 61 M White Non-Hispanic 16 53 209 156 0 2 Y 31108 19746 1677 1336 1677 1336 94 34 4.8 0.4 89 116 1098 134
403* 52 M Asian Non-Hispanic 18 39 174 135 1 4 Y 24462 13614 4060 3187 2107 1164 170 29 0.7 0.13 29 41 3888 179
410 34 M White Non-Hispanic 12 46 192 146 1 2 Y 6355 4353 2456 1730 1249 1112 2.8 1.3 0.36 0.29 25 19 222 65
437 43 F Asian Non-Hispanic 14 34 192 158 1 2 N 15987 6834 3051 1940 3051 1940 16 6.3 0.89 0.23 146 75 699 176
461 49 M White Non-Hispanic 7 39 185 146 2 2 Y 17491 13418 6867 1946 1827 1454 38 44 2 0.46 73 182 1077 361
470 28 F White Non-Hispanic 17 51 173 122 0 2 Y 6054 4894 2315 1798 1003 1025 5.3 3.1 0.2 0.16 90 86 50 14
478 31 M White Non-Hispanic 16 52 172 120 0 1 Y 6600 4083 3238 1824 1264 1283 7.1 3.3 1.8 0.24 33 41 263 15
500 46 M White Non-Hispanic 12 53 207 154 0 2 N 6039 5366 2254 2305 2356 2412 4.2 1.6 0.57 0.2 26 16 194 36
501* 32 M Asian Non-Hispanic 18 53 192 139 0 4 Y 22775 8667 5272 1242 1557 1098 N/A N/A N/A N/A N/A N/A 719 125
506 46 M White Non-Hispanic 12 59 178 119 1 2 Y 3036 2595 1205 975 1338 1041 N/A N/A N/A N/A N/A N/A 10 10
507 39 M White Non-Hispanic 15 60 200 140 0 2 Y 15458 7586 4505 989 1208 1218 22 13 0.88 0.36 104 90 400 49
509 36 M White Non-Hispanic 11 50 190 140 0 2 N 9217 5538 2930 1258 1286 1417 11 4.5 0.41 0.18 165 189 236 36
537 52 M White Non-Hispanic 15 45 178 133 2 2 Y 11285 6443 2448 1083 1245 1192 13 8.6 0.56 0.23 89 52 923 986
539* 73 F White Non-Hispanic 19 55 209 154 1 5 Y 20337 9568 7505 1386 1714 2124 68 41 1 0.65 144 199 488 50
547* 59 M White Non-Hispanic 15 36 211 175 0 3 N 28228 15394 3863 2048 3863 2048 73 33 9.1 0.22 66 140 2901 211
632 38 M White Non-Hispanic 10 43 168 125 0 2 Y 16796 9152 1766 1548 2415 1833 31 12 0.36 0.25 141 153 572 161
633 39 M White Non-Hispanic 8 57 182 125 0 1 N 8759 5108 1436 1224 2019 1404 4.8 3.3 0.25 0.26 121 157 135 32
652* 76 M White Non-Hispanic 18 56 211 155 2 6 N 25025 7388 2748 1433 2748 1433 112 27 1 0.18 79 73 2324 275
664* 45 F White Non-Hispanic 17 42 192 150 0 5 Y 12698 6927 3357 1420 1440 1395 11 4 0.43 0.21 61 26 384 37
674* 41 M White Non-Hispanic 17 57 182 125 0 4 Y 36682 21702 3061 1141 1320 1218 251 57 0.4 0.13 45 66 1619 298
Sx = symptoms
§ = Arterial hypertension (HTN), obesity (OB), diabetes mellitus (DM), asthma (A), chronic obstructive pulmonary disease (COPD), coronary artery disease (CAD), cancer (CX)
¶ = WHO Ordinal Scale for Clinical Improvement, COVID-19 Trial Design Synopsis
† = Persistent fatigue, dyspnea, athletic deficit, or ≥ 3 other solicited symptoms beyond 6 weeks from Sx onset
Reported data are median (range) unless stated otherwise
Neutralization 
(NT50)RBD (AUC)  N (COI)
* = hospitalized, **=asymptomatic
Ethnicity
Acute disease 
severity by 
WHO (0-8) ¶
Sx onset
 to initial visit 
(T1)
Sx onset to 
follow-up visit 
(T2)
Serological assays 
Time 
between 
visits
Post-acute Sx 
persistence † 
# of solicited 
comorbidities §
RBD (Pylon, IV)
Sx duration 
during acute 
disease
Temporal dynamics (days)
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 
The copyright holder for this preprintthis version posted November 5, 2020. ; https://doi.org/10.1101/2020.11.03.367391doi: bioRxiv preprint 
 55 
Supplementary Table 3: Antibody sequences from 1.3 and 6.2 month time point is provided 791 
as a separate Excel file. 792 
Supplementary Table 4: Sequences of the cloned monoclonal antibodies is provided as a 793 
separate Excel file. 794 
Supplementary Table 5: Half maximal effective concentrations (EC50s) of the monoclonal 795 
antibodies is provided as a separate Excel file. 796 
Supplementary Table 6: Inhibitory concentrations of the monoclonal antibodies is provided 797 
as a separate Excel file. 798 
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SI Table 7. Gastrointestinal cohort participant characteristics
Patient ID Cases/controls Age (years) Sex Race Ethnicity Pertinent medical history/comorbidities § Indication Procedure type ‡ Date of procedure
Nasopharyngeal 
SARS-CoV-2 Duodenum Ileum Genomic Subgenomic
CGI088 case 32 M White Non-hispanic seasonal allergies, asthma GERD EGD/COLO June 2020 Negative + + + - - March 2020 May 2020 92 84 2 N
CGI089 case 67 M AA Non-hispanic MM, HTN IDA EGD/COLO July 2020 Negative + + N/A - - March 2020 July 2020 N/A 106 2 N
CGI090 case 73 M White Hispanic gout, HTN, prostate Cx CRC screen, GERD EGD/COLO July 2020 Negative - - N/A - - March 2020 N/A 119 112 2 N
CGI091 case 40 F White Non-hispanic asthma bowel changes EGD/COLO July 2020 Negative - - N/A - - N/A May 2020 N/A N/A 2 N
CGI092 case 70 M White Non-hispanic HTN, HLD CRC screen, GERD EGD/COLO July 2020 Negative + + N/A Duodenum - April 2020 August 2020 N/A 105 2 Y
CGI093 case 48 F N/A Hispanic fibromyalgia, PUD, IDA, psoriasis PUD EGD July 2020 Negative - N/A N/A - - N/A May 2020 121 N/A 2 Y
CGI094 case 30 M White Non-hispanic IBD (Crohn) IBD (Crohn) EGD/COLO August 2020 Negative - - N/A Terminal ileum - April 2020 N/A N/A 113 2 N
CGI095  case 27 F N/A Hispanic allergic rhinitis, GERD IBS EGD/COLO August 2020 Negative - - N/A - - April 2020 N/A N/A 130 2 N
CGI096 case 63 M White Hispanic prostate Cx, ESRD, DM, HTN Rectal bleeding COLO August 2020 Negative N/A - N/A - - April 2020 N/A N/A 148 5 N
CGI097 case 28 M White Non-hispanic IBD (Crohn) IBD (Crohn) COLO August 2020 Negative N/A - N/A - - March 2020 June 2020 N/A 99 1 N
CGI098 case 72 F AA Non-hispanic asthma, HTN, HCV CRC screen EGD/COLO September 2020 Negative - - N/A - - March 2020 N/A N/A 166 2 Y
CGI099 case 70 M AI Non-hispanic CRC, IDA, CAD IDA COLO September 2020 Negative - - N/A Duodenum Duodenum N/A May 2020 173 N/A 2 Y
CGI100 case 30 M White Non-hispanic DM1, CD CD EGD September 2020 Negative + N/A N/A - - N/A May 2020 N/A N/A 1 N
CGI106 case 36 M White Non-hispanic seasonal allergies, asthma abdominal pain, weight loss EGD July 2020 Negative + N/A N/A N/A N/A N/A N/A N/A 113 2 Y
Ctrl 1 control 79 F N/A N/A anemia, renal angiomyolipoma, breast Cx, DM2, HTN gastric ulcer follow up EGD September 2018 N/A - N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A
Ctrl 2 control 79 F N/A N/A Afib, CHF, anemia, HTN, MR weight loss EGD May 2019 N/A - N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A
Ctrl 3 control 55 M N/A N/A GERD, EE abdominal pain EGD July 2019 N/A - N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A
Ctrl 4 control 83 F N/A N/A asthma, CAD, DM2, HTN, GERD, HLD, OA dysphagia EGD July 2019 N/A - N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A
Ctrl 5 control 30 M N/A N/A seasonal allergies, asthma, GERD GERD EGD January 2018 N/A - N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A
Ctrl 6 control 51 F N/A N/A ulnar neuropathy, biceps tendonitis CRC screen COLO April 2019 N/A N/A - N/A N/A N/A N/A N/A N/A N/A N/A N/A
Ctrl 7 control 57 M N/A N/A GERD, HTN, DM2, migraine, OSA, IBS, diverticulosis abdominal pain COLO April 2019 N/A N/A - N/A N/A N/A N/A N/A N/A N/A N/A N/A
Ctrl 8 control 42 M N/A N/A none rectal bleeding COLO September 2019 N/A N/A - N/A N/A N/A N/A N/A N/A N/A N/A N/A
Ctrl 9 control 57 M N/A N/A spinal cord injury, paraplegia, HTN, HLD CRC screen COLO October 2019 N/A N/A - N/A N/A N/A N/A N/A N/A N/A N/A N/A
Ctrl 10 control 33 M N/A N/A DM2, obesity, HTN, heart murmur IDA COLO October 2019 N/A N/A - N/A N/A N/A N/A N/A N/A N/A N/A N/A
AA = African American
AI = Asian Indian
‡ EGD = Esophagogastroduodenoscopy; COLO = colonoscopy
¶ = WHO Ordinal Scale for Clinical Improvement, COVID-19 Trial Design Synopsis
† = Persistent fatigue, dyspnea, athletic deficit, or ≥ 3 other solicited symptoms beyond 6 weeks from symptom onset
* GI symptoms at the time of acute illness including diarrhea, nausea, vomiting
COVID-19 history
SARS-CoV-2 nucleocapsid (N) 
antigen by immunofluorescence 
(IF)
SARS-CoV-2  qPCR
 from intestinal biopsy 
samples
Corona virion-like 
particles by 
electron 
microscopy (EM)
§ = GERD (gastroesophageal reflux disease), CRC (colorectal cancer), IDA (iron deficiency anemia), PUD (peptic ulcer disease), IBD (inflammatory bowel disease), HLD (hyperlipidemia), MV ( mitral valve prolapse), MR (mitral regurgitation), DM (diabetes melitus type 2) OA (osteoarthritis), HTN (arterial hypertension),  COPD (chronic obstructive pulmonary disease), CAD (coronary artery disease), Afib (atrial fibrilation), CHF (congestive heart failure),  OSA 
(obstructive sleep apnea), IBS (irritable bowel syndrome), CD (celiac disease), MM (multiple myeloma), ESRD (end stage renal disease), HCV (hepatitis C), EE (eosinophilic esophagitis), MDD (major depressive disorder), Cx (cancer)
SARS-CoV-2 in the intestine
Positive 
nasopharyngeal 
SARS-CoV-2 
PCR 
Positive SARS-
CoV-2 
serology
Symptom 
onset to GI 
biopsy 
(days)
Positive 
nasopharyngeal 
PCR to GI biopsy 
(days)
Acute 
disease 
severity by 
WHO (0-8) ¶
COVID-19 
associated GI 
symptoms* 
Baseline patient characteristics Gastrointestinal endoscopy 
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